Claims for Patent: 7,772,178

Summary for Patent: 7,772,178

Title:	Pharmaceutical formulations and methods of treatment using the same
Abstract:	Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.
Inventor(s):	Malcolm; Bruce A. (Paoli, PA), Bradley; Prudence K. (Cranford, NJ), Pavlovsky; Anastasia (Morris Plains, NJ), Cho; Wing-Kee Philip (Princeton, NJ), Qiu; Zhihui (Bridgewater, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/444,078
Patent Claims:	1. A pharmaceutical formulation comprising: (a) at least one surfactant present in an amount of about 0.1 to about 10% by weight; and (b) at least one compound wherein said compound is present in an amount of about 50 to about 1000 mg which is: ##STR00622## or a pharmaceutically acceptable salt thereof, wherein said at least one surfactant is selected from the group consisting of sodium lauryl sulfate, monoethanolamine, docusate sodium, poloxamer, lecithin, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, ethoxylated aliphatic alcohols, propylene glycol monocaprylate, glycerol monostearate, medium chain triglycerides, polyoxyethylene alkyl ethers, and polyoxyethylene stearates. 2. The pharmaceutical formulation of claim 1 wherein said at least one surfactant comprises sodium lauryl sulfate. 3. The pharmaceutical formulation of claim 1 wherein said formulation is in capsule form. 4. A method of treating HCV infection comprising administering an effective amount of the pharmaceutical formulation of claim 1 to a subject in need of such treatment. 5. A method of treating a capthesin-associated disorder comprising administering an effective amount of the pharmaceutical formulation of claim 1 to a subject in need of such treatment. 6. The pharmaceutical formulation of claim 2 further comprising 0.1 to 15% by weight of a lubricant. 7. The pharmaceutical formulation of claim 6 wherein the lubricant is magnesium stearate. 8. The pharmaceutical formulation of claim 1 further comprising one or more carriers, binders or disintegrants, or a mixture of two or more thereof. 9. The pharmaceutical formulation of claim 2, further comprising magnesium stearate and one or more carriers, binders or disintegrants, or a mixture of two or more thereof. 10. A pharmaceutical formulation, comprising; (a) a surfactant which is sodium lauryl sulfate present in an amount of about 0.1 to about 10% by weight and (b) at least one compound wherein said compound is present in an amount of about 50 to about 1000 mg which is: ##STR00623## or a pharmaceutically acceptable salt thereof.